Latest news with #XevoTQAbsolute
Yahoo
04-06-2025
- Health
- Yahoo
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
News Summary Up to six-fold increase in performance robustness with StepWave™ XR Ion Guide versus Xevo TQ Absolute.1 Uses up to 50% less power and gas, and occupies up to 50% less bench space than other products in its class.2 Takes the industry-leading sensitivity of Xevo TQ Absolute to new heights, including for PFAS detection and pharma quantitation applications. BALTIMORE and MILFORD, Mass., June 4, 2025 /PRNewswire/ -- 73rd ASMS Conference on Mass Spectrometry and Allied Topics – Waters Corporation (NYSE:WAT) today announced the launch of the Xevo™ TQ Absolute XR Mass Spectrometer, the Company's most sensitive, robust, and reliable benchtop tandem quadrupole. Notably, the product exceeds the performance capabilities of the Xevo TQ Absolute, which itself set the benchmark in the industry for tandem quadrupole sensitivity, particularly in areas such as pharmaceutical quantitation and PFAS detection. Tailored for high-throughput applications in pharmaceutical companies, contract testing organizations, and government laboratories, the new system is designed to deliver exceptional performance for the most sensitive trace-level analyses in complex matrices, while maximizing system uptime and efficiency. "Analytical laboratories are under pressure to adapt to the complex needs of pharmaceutical organizations, and meet the increasing demand for PFAS testing driven by a rapidly evolving regulatory landscape," said James Hallam, Vice President, Liquid Chromatography-Mass Spectrometry, Waters Corporation. "The Xevo TQ Absolute XR design delivers up to a six-fold increase in performance robustness with unmatched sensitivity and resilience to contamination, significantly reducing downtime and enhancing operational efficiency for our customers." Built on the trusted, intuitive design of the Xevo TQ Absolute Mass Spectrometer, the Xevo TQ Absolute XR Mass Spectrometer offers significant operational efficiencies. It uses up to 50% less power and nitrogen gas, produces 50% less heat than any other high-performing tandem or triple quadrupole on the market, and takes up to 50% less bench space, making it the ideal system for laboratories striving to reduce their environmental footprint without compromising throughput or performance. Within the Xevo TQ Absolute XR Mass Spectrometer, Waters introduces the StepWave XR Ion Guide, which incorporates sophisticated technology designed to minimize the risk of unplanned downtime, while preserving high sensitivity and precision for even the most complex sample types and fragile compounds. Through this innovation, customers are realizing a new benchmark of robustness across a wide range of applications, including PFAS, bioanalysis, and genotoxic impurity testing. "Our laboratory requires instrumentation that delivers high-quality, interruption-free results to our customers, helping them to bring safe and effective new drugs to market with confidence and speed," said Sally Hannam, Scientific Director, Synexa Life Sciences, a leading biomarker and bioanalytical services provider. "We are well in excess of 20,000 injections of crashed human plasma continuously analyzed on the Xevo TQ Absolute XR Mass Spectrometer combined with the ACQUITY™ Premier UPLC™ System and waters_connect™ Software, and our early experience is that it demonstrates new levels of reproducibility and accuracy, giving us ever more confidence as we are presented with increasingly challenging bioanalysis applications and new modalities." In addition, the design of the Xevo TQ Absolute XR Mass Spectrometer delivers industry-leading, out-of-the-box quantitation of negatively ionizing compounds, such as PFAS. Bioanalytical, food safety, and environmental testing laboratories will benefit from the high confidence results and operational efficiency gains that the Xevo TQ Absolute XR Mass Spectrometer delivers. The Xevo TQ Absolute XR Mass Spectrometer is available to order now. Additional Resources Product Page Waters, StepWave, ACQUITY, UPLC, waters_connect, and Xevo are trademarks of Waters Technologies Corporation. ABOUT: Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science. Contact: Molly GluckHead of External CommunicationsWaters Corporationmolly_gluck@ +1.617.833.8166 Application Note on Product Webpage. In a well-controlled experiment, performance was maintained for up to six times the duration on the Xevo TQ Absolute XR compared to the Xevo TQ Absolute; more than 12,000 samples of pesticides in fish feed matrix were analyzed. Based on a comparison of high-end tandem and triple quadrupole instruments available on the market. [Infographic] View original content: SOURCE Waters Corporation Sign in to access your portfolio
Yahoo
02-06-2025
- Business
- Yahoo
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
News Summary Up to six-fold increase in performance robustness with StepWave™ XR Ion Guide versus Xevo TQ Absolute.1 Uses up to 50% less power and gas, and occupies up to 50% less bench space than other products in its class.2 Takes the industry-leading sensitivity of Xevo TQ Absolute to new heights, including for PFAS detection and pharma quantitation applications. BALTIMORE and MILFORD, Mass., June 2, 2025 /PRNewswire/ -- 73rd ASMS Conference on Mass Spectrometry and Allied Topics – Waters Corporation (NYSE:WAT) today announced the launch of the Xevo™ TQ Absolute XR Mass Spectrometer, the Company's most sensitive, robust, and reliable benchtop tandem quadrupole. Notably, the product exceeds the performance capabilities of the Xevo TQ Absolute, which itself set the benchmark in the industry for tandem quadrupole sensitivity, particularly in areas such as pharmaceutical quantitation and PFAS detection. Tailored for high-throughput applications in pharmaceutical companies, contract testing organizations, and government laboratories, the new system is designed to deliver exceptional performance for the most sensitive trace-level analyses in complex matrices, while maximizing system uptime and efficiency. "Analytical laboratories are under pressure to adapt to the complex needs of pharmaceutical organizations, and meet the increasing demand for PFAS testing driven by a rapidly evolving regulatory landscape," said James Hallam, Vice President, Liquid Chromatography-Mass Spectrometry, Waters Corporation. "The Xevo TQ Absolute XR design delivers up to a six-fold increase in performance robustness with unmatched sensitivity and resilience to contamination, significantly reducing downtime and enhancing operational efficiency for our customers." Built on the trusted, intuitive design of the Xevo TQ Absolute Mass Spectrometer, the Xevo TQ Absolute XR Mass Spectrometer offers significant operational efficiencies. It uses up to 50% less power and nitrogen gas, produces 50% less heat than any other high-performing tandem or triple quadrupole on the market, and takes up to 50% less bench space, making it the ideal system for laboratories striving to reduce their environmental footprint without compromising throughput or performance. Within the Xevo TQ Absolute XR Mass Spectrometer, Waters introduces the StepWave XR Ion Guide, which incorporates sophisticated technology designed to minimize the risk of unplanned downtime, while preserving high sensitivity and precision for even the most complex sample types and fragile compounds. Through this innovation, customers are realizing a new benchmark of robustness across a wide range of applications, including PFAS, bioanalysis, and genotoxic impurity testing. "Our laboratory requires instrumentation that delivers high-quality, interruption-free results to our customers, helping them to bring safe and effective new drugs to market with confidence and speed," said Sally Hannam, Scientific Director, Synexa Life Sciences, a leading biomarker and bioanalytical services provider. "We are well in excess of 20,000 injections of crashed human plasma continuously analyzed on the Xevo TQ Absolute XR Mass Spectrometer combined with the ACQUITY™ Premier UPLC™ System and waters_connect™ Software, and our early experience is that it demonstrates new levels of reproducibility and accuracy, giving us ever more confidence as we are presented with increasingly challenging bioanalysis applications and new modalities." In addition, the design of the Xevo TQ Absolute XR Mass Spectrometer delivers industry-leading, out-of-the-box quantitation of negatively ionizing compounds, such as PFAS. Bioanalytical, food safety, and environmental testing laboratories will benefit from the high confidence results and operational efficiency gains that the Xevo TQ Absolute XR Mass Spectrometer delivers. The Xevo TQ Absolute XR Mass Spectrometer is available to order now. Additional Resources Product Page Waters, StepWave, ACQUITY, UPLC, waters_connect, and Xevo are trademarks of Waters Technologies Corporation. ABOUT: Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science. Contact: Molly GluckHead of External CommunicationsWaters Corporationmolly_gluck@ +1.617.833.8166 Application Note on Product Webpage. In a well-controlled experiment, performance was maintained for up to six times the duration on the Xevo TQ Absolute XR compared to the Xevo TQ Absolute; more than 12,000 samples of pesticides in fish feed matrix were analyzed. Based on a comparison of high-end tandem and triple quadrupole instruments available on the market. [Infographic] View original content to download multimedia: SOURCE Waters Corporation
Yahoo
13-02-2025
- Business
- Yahoo
Waters Corp (WAT) Q4 2024 Earnings Call Highlights: Strong Pharma and PFAS Growth Amid FX Challenges
Revenue Growth: 6.4% as reported and 8% in constant currency for Q4 2024. Adjusted EPS Growth: 13% to $4.10 in Q4 2024; 22% growth excluding FX impact. GAAP EPS: $3.88 for Q4 2024. Full-Year Non-GAAP EPS: $11.86, reflecting 1% growth with a 5% decline due to FX headwinds. Full-Year GAAP EPS: $10.71 per share. Operating Margin: 35.5% adjusted operating margin in Q4 2024, a 60 basis point increase. Free Cash Flow: $188 million in Q4 2024; $744 million for the full year. Net Debt Position: Approximately $1.3 billion, with a net debt-to-EBITDA ratio of about 1.3 times. Pharma Sales Growth: 10% in Q4 2024, with low double-digit growth in Europe and Asia. Instrument Sales Growth: 8% in Q4 2024, led by LC, Mass Spec, light scattering, and TA systems. Recurring Revenue Growth: 9% in Q4 2024, with chemistry and service both up high single digits. PFAS Revenue Growth: Over 40% in Q4 2024 and for the year. Max Premier Columns Sales Growth: Over 30% in Q4 2024 and over 40% for the year. 2025 Sales Growth Guidance: 4.5% to 7% in constant currency. 2025 EPS Guidance: $12.70 to $13 on a non-GAAP basis, reflecting 7% to 10% growth. Warning! GuruFocus has detected 6 Warning Signs with WAT. Release Date: February 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Waters Corp (NYSE:WAT) achieved high single-digit constant currency revenue growth and low-teens adjusted EPS growth in Q4 2024. Pharma sales, the largest end market for Waters Corp (NYSE:WAT), grew in low double digits, indicating strong demand. Recurring revenues grew 9%, marking an improvement from the previous quarter, with chemistry and service both up high single digits. The Xevo TQ Absolute system, a key product, saw unit sales grow 40% year-over-year, contributing significantly to PFAS testing revenue growth. Waters Corp (NYSE:WAT) achieved a 60 basis point increase in adjusted operating margin to 35.5%, despite FX headwinds. Sales for the full year were flat as reported and in organic constant currency terms, indicating challenges in overall growth. The US dollar's strengthening introduced significant foreign exchange headwinds, impacting financial performance. The Academic and Government segment saw a decline of 7% for the full year, reflecting challenges in this market. China sales, while returning to positive growth, only increased by low single digits, indicating a slow recovery. The company faces ongoing margin challenges, including FX, inflation, and normalization of annual incentive compensation. Q: Can you elaborate on the budget flush dynamics and the replacement cycle within your pharma customer base? A: Udit Batra, President and CEO, explained that 2024 saw a typical budget flush with a high-teens ramp from Q3 to Q4, driven by strong sales momentum. The replacement cycle is progressing well, with large pharma initiating replacements, and the Alliance iS now constituting 20% of HPLC sales. The replacement cycle is widespread among large pharma and CDMOs, with strong funnels going into 2025. Q: How are macroeconomic risks, such as tariffs and potential spending cuts, factored into your 2025 guidance? A: Udit Batra noted that the 2025 guidance of 4.5% to 7% sales growth incorporates these risks. The recurring revenue growth is expected to remain stable at 6% to 7%, while instruments need to grow 4% to 4.5% to reach the midpoint of the guidance. The company has built prudence into the lower end of the guidance to account for potential headwinds. Q: What is the expected contribution from PFAS, GLP-1, and India to the 2025 growth? A: Udit Batra stated that both GLP-1 and PFAS are expected to contribute 30 basis points each to growth, while India is anticipated to add 70 to 100 basis points. India showed over 25% growth in 2024, and China is expected to maintain low single-digit growth with potential upside from stimulus. Q: Can you discuss the strength in the academic and government segment and expectations for 2025? A: Amol Chaubal, CFO, mentioned that Q4 saw strong growth due to typical budget flush dynamics, especially in Europe, and initial orders from China's stimulus. For 2025, the company expects low single-digit growth in this segment, with limited direct exposure to NIH funding risks. Q: How is the PFAS market evolving, and what drives Waters' growth in this area? A: Udit Batra highlighted that the PFAS market is expanding due to new applications in environmental, food, and academic testing. Waters is growing faster than the market, driven by the Xevo TQ Absolute's sensitivity and low environmental footprint, along with strong informatics and chemistry offerings. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
